Replies to post #36272 on Biotech Values

[Biowatch]

>Achillion – Yet another biotech IPO going
off below the lower bound of the expected
price range.<

Is that due to poor market conditions in general, or in biotech, or because of the current competition in their market niche?

and I will skip jokes about Achilles tendon...

[DewDiligence]

With three biotechs down more than 30% today,
people may have missed that ACHN was up on
its first day of trading. However, this outcome
is tainted because the IPO went off at a bargain
basement price.

[DewDiligence]

ACHN – With the large cut that underwriters take, one might think they could gauge demand more accurately so clients would not leave money on the table. ACHN filed to IPO at $14-16 but went off at $11.50 last Thursday and quickly rose above $14: